Coeptis Therapeutics Holdings, Inc. News
-
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
Bolsters Company’s Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price June 20,…
-
Coeptis Therapeutics’ Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
May 30, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
May 08, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative…
-
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
May 02, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor’s Distinguished Research Award
April 2, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing…
-
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR…
-
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which…
-
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
January 4, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing…
-
Coeptis Therapeutics to Present at the Emerging Growth Conference
December 4, 2023 (Source) — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing…